Lynne Kelley

Lynne Kelley

Chief Medical Officer

Lynne Kelley is the Chief Medical Officer for Servier Pharmaceuticals helping to drive strategy and enable the business to achieve its goals for sustainable growth.

Lynne is a general and vascular surgeon and member of the American College of Surgeons. She brings over 15 years of industry experience across a wide array of therapeutic areas including oncology, rare and orphan diseases. She has led global teams of medical professionals spearheading innovation, due diligence, clinical trials (ranging from novel drug products, biologics, medical devices and drug-device combinations including being a principal investigator), safety evaluations, product development and key opinion leader management. She has served as an executive of the medical functions at multi-national companies such as Becton Dickinson and Kimberly Clark and as Chief Medical Officer for Senseonics, Histogenics, and most recently X4 Pharmaceuticals. 

Lynne received her Doctor of Medicine from Dartmouth Medical School, completed her surgical residency at Dartmouth Hitchcock and her vascular surgery fellowship at Massachusetts General Hospital. She was awarded the inaugural Marco Polo Fellowship allowing her to further study endovascular surgery at Hospital Henri Mondor in Paris, France. During her residency, she was awarded an NIH T-32 training grant for basic science research in vascular biology and apoptosis. She was an assistant professor of vascular surgery and interventional radiology at Yale University before moving to industry. Lynne is on the board of advisors for the Center of Health Equity at Dartmouth Medical School and is on the board of directors for Equalize Health (formerly D-Rev). 

To learn more about Lynne connect with her on LinkedIn.

More from Servier

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More


Servier Pharmaceuticals is an independent, privately held United States company launched by Servier Group, a unique global organization, and is governed by a non-profit foundation.

Learn More


Servier has a 65-year history of helping provide innovative medicines to patients globally. In the United States, Servier intends to uphold and build upon that history. 

Learn More